New software to capture worldwide cancer data

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Researchers from Queen’s University Belfast, the Northern Ireland Cancer Registry, the International Agency for Research on Cancer and the Union for International Cancer Control have developed CanStaging+, a user-friendly tool aimed at facilitating the recording of comparable cancer staging data worldwide.

The collection of staging data at population-level is currently undertaken by population-based cancer registries. There is a large variation of data collected making it difficult to benchmark and to develop global strategies.

“Almost half of registries in Latin America and the Caribbean (52%) report staging information compared to 96% of registries in North America and Europe,” said Anna Gavin, who led the work from the Northern Ireland Cancer registry Centre for Public Health at Queen’s University Belfast.

A lack of data and inconsistency is a huge problem in high-income countries too where there were 6-37% of missing staging data for colorectal cancer across seven countries within the International Cancer Benchmarking Partnership between 2010 and 2014.

To mark the launch of the CanStaging+ tool, an accompanying article has been published in The Lancet Oncology.

Table of Contents

YOU MAY BE INTERESTED IN

George F. Tidmarsh has resigned from his job as director of the FDA Center for Drug Evaluation and Research in the aftermath of a lawsuit by a former associate and a probe into what an HHS spokesperson described as “serious concerns about his personal conduct.”
Research has shown that delivering tumor profiling results to cancer patients prior to initiation of treatment and connecting patients harboring an actionable oncogenic mutation with the right targeted therapy can deliver superior patient outcomes. To fulfill this promise of precision medicine, we need to ensure more targeted therapies are available to patients who need them. Fortunately, this work is well underway. xxx:more

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login